According to clinical trial data published online in the scientific journal Digestion, cannabis inhalation increases quality of life, mitigates disease activity, and promotes weight gain in subjects with inflammatory bowel disease (IBD).
Investigators at the Chaim Sheba Medical Center in Tel Aviv, Israel assessed the effectiveness of inhaled prescription cannabis in patients with long-standing IBD, such as Crohn’s disease.
Researchers reported: “After three months’ treatment, patients reported improvement in general health perception, social functioning, ability to work, physical pain and depression. A schematic scale of health perception showed an improved score. … Patients had … weight gain … during treatment and an average rise in BMI (body mass index).”
They concluded, “Three months’ treatment with inhaled cannabis improves quality of life measurements, disease activity index, and causes weight gain and rise in BMI in long-standing IBD patients.”
It is believed that around 6,000 Israelis are supplied with locally grown cannabis for therapeutic purposes as part of a limited government program.
An estimated one-third of patients with colitis and one-half of subjects with Crohn’s acknowledge having used cannabis to mitigate their disease symptoms, according to survey data published in August in the European Journal of Gastroenterology and Hepatology.
Impact of Cannabis Treatment on the Quality of Life, Weight and Clinical Disease Activity in Inflammatory Bowel Disease Patients: A Pilot Prospective Study-Digestion